This is because RTX has only approved for the treatment of non-Hodgkin’s B cell lymphoma, chronic lymphocytic leukemia, Wegener’s granulomatosis, and in patients with rheumatoid arthritis who are not responding to TNF-α blockers (U.S. Food and Drug Administration, 2012). Here, TNF is linked to B-cell chronic lymphocytic leukemia.